asparaginase

L-Asparaginase (L-ASNase) (L-ASNase), a hydrolase that catalyzes the conversion of L-asparagine, used in acute lymphoblastic leukemia treatment.Asparaginase is an enzyme that is used as a medication. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin.

D-Asparagine (H-D-Asn-OH) serves as a nitrogen source for yeast strains and acts as a competitive inhibitor of L-Asparagine hydrolysis with a Ki of 0.24 mM.

Asparaginase Erwinia chrysanthemi (Crisantaspase) exhibits specific anti-acute lymphoblastic leukemia (ALL) activity and also depletes glutamine, inhibiting the growth of hepatocellular tumors in mouse models [1] [2].

1-Monopalmitin (Glyceryl palmitate) is a small molecule compound extracted from Mougeotia nummuloides and Spirulina major with potential antitumor activity, inhibiting proliferation of A549 and SPC-A1 cells, and inducing G2/M blockade and cysteinyl asparaginase-dependent apoptosis.

SACLAC is a cysteine asparaginase activation inhibitor with antitumor activity that decreases AML cell viability, inhibits AML cell proliferation, increases AML cell death, and induces apoptosis of AML cells, and is used in the study of acute myeloid leukemia and cancer.

ASX-173 is an orally active asparagine synthetase (ASNS) inhibitor with an IC50 of 0.113 μM and a Ki of 0.4 nM. It enhances the anticancer activity of L-Asparaginase (ASNase). When combined with ASNase, ASX-173 disrupts nucleotide synthesis and induces cell cycle arrest, apoptosis (apoptosis), and autophagy (autophagy) in leukemia cells. This combination also slows the growth of OCI-AML2 xenograft tumors. ASX-173 is applicable in research on acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers.

GCN2iB is a GCN2 inhibitor. GCN2iB may be useful for the treatment of cancer. The inhibition of GCN2 sensitizes cancer cells with low basal-level expression of asparagine synthetase (ASNS) to the antileukemic agent L-asparaginase (ASNase) in vitro and in vivo.

Sanggenol L, a compound from the root bark of Morus alba, inhibits cell growth and promotes apoptotic cell death in melanoma skin cancer cells through activation of the cysteinyl asparaginase cascade and apoptosis-inducing factors. Sanggenol L has anticancer activity and antiproliferative effects and is used in the study of prostate cancer.